ZETIA Drug Patent Profile

Which patents cover Zetia, and what generic alternatives are available?

Zetia is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-five patent family members in thirty-eight countries.

The generic ingredient in ZETIA is ezetimibe. There are twenty-four drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ezetimibe profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zetia

A generic version of ZETIA was approved as ezetimibe by GLENMARK PHARMS LTD on June 26^th, 2015.

Summary for ZETIA

International Patents:	235
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Patent Applications:	5,609
Drug Prices:	Drug price information for ZETIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZETIA
What excipients (inactive ingredients) are in ZETIA?	ZETIA excipients list
DailyMed Link:	ZETIA at DailyMed

See drug prices for ZETIA

See drug sales revenues for ZETIA

Pharmacology for ZETIA

Drug Class	Dietary Cholesterol Absorption Inhibitor
Physiological Effect	Decreased Cholesterol Absorption

Paragraph IV (Patent) Challenges for ZETIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZETIA	Tablets	ezetimibe	10 mg	021445	1	2006-10-25

US Patents and Regulatory Information for ZETIA

ZETIA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	AB	RX	Yes	Yes	7,612,058*PED				Y

Expired US Patents for ZETIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	5,767,115

International Patents for ZETIA

See the table below for patents covering ZETIA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	180249
Australia	681445
Australia	7795294
Brazil	1100159
Canada	2172149	DERIVES DE SUBSTITUTION HYDROXYLES D'AZETIDINONE, UTILES COMME AGENTS HYPOCHOLESTEROLEMIQUES (HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS)
China	1050830
China	1131416

Supplementary Protection Certificates for ZETIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	300132	Netherlands		300132, 20140914, EXPIRES: 20171016
0720599	0390018-0	Sweden		PRODUCT NAME: EZETIMIB
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599	SPC/GB03/023	United Kingdom		PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
0720599	SZ 20/2003	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON
0720599	SPC014/2003	Ireland		SPC014/2003: 20050803, EXPIRES: 20171016
0720599	CA 2005 00003	Denmark

Last updated: July 29, 2026

Zetia (ezetimibe) Market Dynamics and Financial Trajectory: Sales, Competition, Exclusivity, and Patent-Driven Generic/Biosimilar Outlook

Zetia (ezetimibe) revenue has been shaped by (1) loss of broad first-line commercial exclusivity in the late 2010s, (2) sustained share competition from low-cost statins and combination therapies, and (3) patent and regulatory milestones that have enabled multiple generic and authorized alternatives. The core market reality: Zetia’s long-term growth has been constrained by generic entry risk, channel substitution, and payer preference for statin-based regimens, with ezetimibe value concentrated in add-on use and cardiovascular-risk subpopulations rather than primary lipid therapy.

---

How has Zetia (ezetimibe) performed financially over time?

Zetia’s financial trajectory is best read as two phases: early growth driven by branded uptake, followed by a plateau as generics and combination alternatives reduced pricing power.

Sales path by era (high-level dynamics)

• Launch-to-peak period: Brand uptake was supported by a clear mechanism (NPC1L1 inhibition) and clinical positioning as add-on to statins or for patients unable to take statins.
• Post-exclusivity period: Pricing compression and formulary narrowing followed the erosion of brand exclusivity and the entry of low-cost generics.
• Recent steady-state: Sales persist because ezetimibe has a durable niche in cardiovascular risk management, but unit growth is offset by continuing net price pressure and competition.

What drives ongoing revenue

• Payer coverage logic: Ezetimibe is frequently covered when patients are inadequately controlled on statins or cannot tolerate statins.
• Provider prescribing habits: Clinicians use ezetimibe to reach guideline LDL-C targets without escalating statin dose beyond tolerability thresholds.
• Fixed-dose combinations: Market share has migrated to combination products (notably ezetimibe/rosuvastatin) where available and clinically appropriate.

---

What are the key market dynamics affecting Zetia’s demand?

1) Competition with statins and guideline-driven lipid management

Statins remain the dominant class in initial LDL-C lowering. Ezetimibe benefits when:

• LDL-C targets are not reached on maximally tolerated statin therapy, or
• patients are statin-intolerant or have contraindications.

2) Shift to fixed-dose combinations

Combination therapy reduces pill burden and can simplify titration for payers. This structurally pressures single-agent Zetia demand.

3) Generic price erosion

Once generics establish, brand net price typically declines and volume growth slows unless:

• a payer restricts generics more tightly, or
• brand has unique formulary status (rare long-term).

4) Medical and purchasing channel factors

• 340B/contract pharmacy economics and PBM formulary placement influence net realizations.
• High rebate environments reduce the durability of brand pricing.

---

What is the competitive landscape for ezetimibe in the US?

Brand vs generics

• Zetia is the brand for ezetimibe monotherapy.
• Multiple generic ezetimibe manufacturers compete on price.
• Combination products (ezetimibe with statins) can displace single-agent use depending on patient phenotype and payer policy.

How the competitive set changes by payer segment

• Commercial: Typically faster formulary adoption of generics and preference for combinations when step edits exist.
• Medicare Part D: Often includes broad generic coverage; brand use persists only if step therapy is satisfied with exceptions.
• Managed Medicaid: Can be strict on brand use and reward lower ASP equivalents.

---

How does Zetia compare with simvastatin/ezetimibe and ezetimibe/rosuvastatin combinations?

Clinical positioning

• Single-agent ezetimibe is used when statins are contraindicated or as add-on to reduce LDL-C further.
• Fixed-dose combinations can be used earlier in escalation pathways, especially where LDL-C targets are aggressive.

Market impact

• In payers that enforce step edits for single-agent ezetimibe, combination products can gain share.
• Where formularies include ezetimibe/rosuvastatin or other combos at preferred tiers, Zetia faces substitution even in add-on use cases.

---

When does Zetia lose exclusivity, and how does that affect pricing?

Zetia’s broader exclusivity window ended years ago, enabling generic entry for ezetimibe. The commercial imprint is a long-running pattern: brand volume stabilizes at lower levels while brand net price falls toward competitive parity.

Typical post-exclusivity effect timeline

• Pre-generic entry: Brand price supported by limited competition and patent protection.
• At generic entry: Wholesale pricing and PBM positioning shift rapidly.
• 6 to 24 months post-entry: Net revenue stabilizes at lower net pricing as contracts adjust.

---

What patents protect ezetimibe products like Zetia, and how strong is the patent estate?

Patent estate pattern for Zetia

Ezetimibe is a small-molecule with a well-established core IP footprint. Over time, most value shifts from primary compound protection toward:

• formulation,
• process,
• method-of-use claims,
• and life-cycle extensions (if any) that can delay specific generic versions.

Commercially relevant implication

Even where secondary patents exist, the long-term market effect is limited once broad generic coverage exists for the main dosage form and approved indications.

---

What generic entry risks exist for Zetia?

Generic entry for ezetimibe is already realized in practical terms: the key business risk is no longer “will generics enter,” but:

• how quickly additional manufacturers expand distribution, and
• whether new formulations or combinations shift share away from monotherapy.

Risk drivers to monitor

• New Paragraph IV cases are less likely to be the primary determinant now versus early years.
• The more immediate competitive driver becomes PBM rebate dynamics and combination conversion.

---

What does FDA regulatory status imply for future Zetia revenues?

Approved uses remain durable

Zetia’s continued revenue comes from persistent guideline role in LDL-C reduction strategies.

Regulatory implications for growth

• As generics are already widely available, future revenue upside is limited to:
  • incremental label expansions (if any remain),
  • switching to higher-value regimens,
  • or sustained payer coverage of ezetimibe add-on therapy.

---

How do payer and PBM dynamics affect Zetia net sales?

Net sales typically track formulary status

• If Zetia is on preferred tiers, the brand can retain some unit share despite generic availability.
• If it moves to non-preferred tiers, brand unit share falls and net revenue compresses.

Rebate economics

Net realizations for brands depend on:

• rebate size,
• channel mix,
• contracting timing relative to generic entry.

---

How does Zetia’s revenue mix compare with higher-growth cardiovascular drugs?

Compared with newer cardiovascular brands (PCSK9 inhibitors, LDL-lowering therapies with broader protected structures), ezetimibe faces:

• lower payer willingness to pay premium prices once generics exist,
• substitution pressure from therapies with stronger LDL-C lowering per dose.

Zetia competes by being:

• oral,
• relatively low cost (when generic),
• and useful as part of combination titration.

---

What’s the financial trajectory for ezetimibe makers versus Zetia brand owner economics?

Brand owner

Brand economics depend on:

• remaining protected share,
• net pricing and rebates,
• contract retention in major wholesaler and PBM channels.

Generic makers

Generic profitability depends on:

• ASP stability,
• manufacturing scale,
• ANDA exclusivity for specific strengths or 505(b)(2) adjacent products (where applicable),
• distribution contracts.

Resulting market behavior

Even when unit demand is stable, brand owner margins typically compress due to:

• competitive pricing,
• rebate pressure,
• and share drift to generics and combinations.

---

What commercial metrics should be used to track Zetia’s outlook?

Use a three-layer scorecard:

1. Prescription and patient share

   • Total ezetimibe scripts
   • Proportion Zetia vs generic ezetimibe
   • Proportion of ezetimibe use that is monotherapy vs combination

2. Pricing and net revenue

   • Brand net sales and average net price
   • Generic ASP trends for ezetimibe and combinations

3. Formulary position

   • Preferred vs non-preferred tier placement
   • Step edits and prior authorization frequency
   • PBM rebate changes

---

What is the likely medium-term trajectory for Zetia revenue?

The medium-term pattern is likely continued:

• volume stability or slow growth driven by clinical need for add-on LDL lowering in statin inadequacy/tolerance scenarios,
• continued price pressure as generic penetration stays high and combination options capture incremental share,
• limited upside absent new clinically transformative label expansions that alter payer behaviors.

---

Key Takeaways

• Zetia’s long-run financial performance is constrained by generic competition and substitution to combination regimens.
• The demand base remains durable in guideline add-on and statin-intolerance niches, but monetization weakens as pricing normalizes post-exclusivity.
• Medium-term growth is more likely to track patient need and combination conversion than to rely on brand premium pricing.

---

FAQs

1) Will Zetia still be preferred when ezetimibe generics are cheaper?

Preference depends on PBM tier placement and rebate economics; in many formularies, cheaper generics reduce brand preference except where specific contract incentives apply.

2) What drives ezetimibe use among statin-intolerant patients?

Guideline-based lipid control strategies and clinical need for LDL-C reduction without tolerability tradeoffs drive add-on or alternative therapy choices.

3) Does combination therapy reduce Zetia monotherapy prescriptions?

Yes. Fixed-dose combinations can capture share by simplifying regimens and aligning with payer coverage structures.

4) How sensitive is Zetia to shifts in PBM formularies?

High. PBM tier movement and prior authorization policies can quickly shift volume between brand and generics.

5) What is the main commercial risk for Zetia going forward?

Ongoing pricing compression from generic availability and continued substitution toward combination products rather than new entrants to the ezetimibe monotherapy market.

---

References

No sources were cited.

DrugChatter Q&A for ZETIA

Foods not to eat with zetia?
Zetia combined with vascepa?
Is it recommended to take zetia and vascepa together?
Does fiber interfere with zetia?
Can i drink alcohol and use zetia?